Erez Chimovits
CIK 1706399 · last filed 2026-09-30
Erez Chimovits is a corporate insider who has filed 24 SEC Form 4 insider transactions across 8 companies since 2018. The most recent filing, for ADRX, was dated Sep 30, 2026. Across all open-market trades the lifetime net is +$65.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.8M across reported positions. 4 SEC filings were submitted jointly with OrbiMed Israel BioFund GP Limited Partnership.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BRVE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADRX | Director | 7,127,019 | — | — | $1.05M | 1 | 2026-09-30 |
| Braveheart Bio, Inc. (BRVE) Delisted | Director | 10,235,159 | $21.87 | $223.84M | $34.92M | 3 | 2026-08-11 |
| UPB | Director | 973,716 | $2.75 | $2.68M | $14.03M | 4 | 2026-06-11 |
| BiomX Inc. (PHGE.U) Delisted | 10%+ Owner | 13,797,997 | $0.90 | $12.42M | -$37.1K | 2 | 2024-05-20 |
| ACET | Director | 43,128 | $3.94 | $169.9K | $0 | 2 | 2021-02-18 |
| LogicBio Therapeutics, Inc. (LOGC) Delisted | Director | 4,126,972 | $7.06 | $29.14M | $13.79M | 5 | 2020-10-05 |
| BiomX Inc. (PHGE.WS) Delisted | Director | 2,313,489 | $0.01 | $20.4K | $199.2K | 4 | 2020-03-27 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | 176,851 | — | — | $2.00M | 3 | 2020-02-25 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-30 | ADRX | Mixed | +9,292,025 | $1.05M | EDGAR |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) Delisted | Mixed | +11,072,420 | $34.92M | EDGAR |
| 2026-08-07 | Braveheart Bio, Inc. (BRVE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-08-07 | Braveheart Bio, Inc. (BRVE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | UPB | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-10-17 | UPB | Mixed | +4,434,789 | $14.03M | EDGAR |
| 2024-10-15 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-05-20 | BiomX Inc. (PHGE.U) Delisted | Mixed | +37,024,256 | $9.02M | EDGAR |
| 2024-03-19 | BiomX Inc. (PHGE.U) Delisted | Buy (P) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.